BioNTech joins Biologics Pharma Innovation Programme Singapore consortium

The consortium aims to grow Singapore’s capabilities in biologics manufacturing.

The Biologics Pharma Innovation Programme Singapore (BioPIPS) consortium welcomed global immunotherapy company BioNTech to its roster of members.

The consortium, led by A*STAR, aims to increase productivity and sustainability in biologics manufacturing, transforming the existing base of biologics production in Singapore.

The consortium focuses on biologics products, including recombinant therapeutic proteins and vaccines, which were vital during the COVID-19 pandemic.

BioPIPS consortium includes GSK, Sanofi, Nanyang Technological University, Singapore (NTU), NTUitive, National University of Singapore (NUS), and Singapore Institute of Technology (SIT).

Consortium members inked a Memorandum of Understanding (MoU) in 2022, which enabled discussions on manufacturing challenges for potential research projects.

Follow the link for more news on

A*STAR

Singapore

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia